"Actualites pharmaceutiques", ARCHIVES DE PEDIATRIE, ELSEVIER, PARIS, FR, vol. 13, no. 12, 1 December 2006 (2006-12-01), pages 1596-1598, XP027997707, ISSN: 0929-693X, DOI: 10.1016/J.ARCPED.2006.09.019 [retrieved on 2006-12-01] (B1)

Website of the European Respiratory Society, http://www.ers-cducation.org/cvvnts/intcma tional-congrcsx/*tockholm-2007.axpx?idParc ni=l425 (B2)

Aclidinium bromide improves exercise endurance and dynamic hyperinflation and decreases exertional dyspnoeain patients with moderate-to-severe COPD. the American Thoracic Society 2013 International Conference. (B1)

Anonymous: "Aerosols, nasal sprays, metered dose inhalesr and dry powder inhalers"; "<601>" In: Anonymous: "United States Pharmacopeia 36", 1 May 2013 (2013-05-01), The United States Pharmacopeial Convention pages 1-22, (B1)

Anonymous: "Guideline on the pharmaceutical quality of inhalation and nasal products" In: Anonymous: "The European Medicines Agency CHMP Guidelines", 1 October 2006 (2006-10-01), The European Medicines Agency, London, UK pages 1-27, (B1)

DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US NLM17136971, March 2005 DONOHUE JAMES F: 'Minimal clinically important differences in COPD lung function.' Database accession no. NLM17136971 (B1)

G. JOOS ET AL.: "Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study" , [Online] 16 September 2007 (2007-09-16), pages 209S-210S, XP002487868 Retrieved from the Internet: URL:http://www.ersnet.org/learning_resourc es_player/abstract_print_07/files/138.pdf> [retrieved on 2008-07-10] (B1)

US-A1- 2005 025 718 (B1)

US-A1- 2005 026 948 (B1)

WO-A-02/36106 (B1)

"Aclidinium bromide, a novel inhaled long-acting anticholinergic - A review of data presented at the European Respiratory Society 2007". by Per-Olof Andersson. Executive Director.R & D, Alnirall, Barcelona. Spain. Presented on September 17, 2007. (B2)

2006 Guidelines issued by the Global Initiative for Chronic Obstructive Lung Disease (B2)

A. Gavalda et al.. ?Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance", Eur. Rcspir. J 30 (Suppl. 51): pages209s - 210s (2007), Abstract 1296 (B2)

AU-B2- 2005 202 144 (B2)

C. Fenton ct al.. Drugs 63(22). 2437-45 (2003) (B2)

D. Singh ct al.. Pulmonary Pharmacology & Therapeutics 25. 248-253 (2012), including a corrigendum published in 2013 (B2)

E.M. Kerwin ct al.. COPD 9. 90-101 (2012) (B2)

Enlarged and full-color copies of Figures 2(a). 2(b) and 3 from D2. (B2)

European Medicines Agency, Committee for medicinal products lor human use (CHMP).Guideline on the pharmaceutical quality of inhalation and nasal products. Doc Ref.:EMEA/CHMP/QWP/49313/2005 Corr (B2)

European Respiratory Society (ERS) webpage relating to the presentation of DI and D2.September 16. 2007. pages 209s-2l0s (B2)

Extract from Martindale "The Extra Pharmacopoeia". 29th Ed., page 522 (1989) (B2)

F.M. Etzleret al., Part. Part. Syst. Charact. 12(5), 217-24 (1995) (B2)

Food and Drug Administration, Center for Drag Evaluation and Research. "Pharmacology Review(s) - NDA No. 21-077". August 24. 2000 (B2)

Food and Drug Administration. Center for Drag Evaluation and Research. ?Pharmacology Revicw(s) - NDA No. 20-831". February 16. 2001 (B2)

Food and Drug Administration. Center for Drag Evaluation and Research. ?Pharmacology Review(s) - NDA No. 20-833". September 29. 2000. (B2)

G.F. Joos cl al., "Bronchodilator effects on aclidinium bromide, a novel long-actinganticholinergic, in COPD patients: a Phase II study" Abstract presented al the Annual Congress of the European Respirator}' Society (ERS) in Stockholm. Sweden. September 16, 2007 (B2)

G.F. Joos et al., "Bronchodilator effects on aclidinium bromide, a novel long-actinganticholinergic, in COPD patients: a Phase II study". Poster presented at the Annual Congress of the European Respiratory Society (ERS) in Stockholm. Sweden. September 16. 2007 (B2)

G.F. Joos et al.. Respiratory Medicine 104, 863-872 (2010) (B2)

Gross cl al.. Respiratory Medicine 102. 189-197 (2008). published online on December 3.2007 (B2)

H. Steckel ct al.. Eur. J Pharm. Biopharm. 57(3). 495-505 (2004) (B2)

H.G. Brittain. Pharmaceutical Technology 25(7), 96-8 (2001) (B2)

H.W. Frijlink el al.. Expert Opin. Drug Deliv. 1(1), 67-86 (2004) (B2)

Joint declaration from Kathrin Block and Roland Greguletz, December 15, 2016 (B2)

L.P. Boulet el al.. Canadian asthma consensus report. 1999: Inhalation devices and propellants. CMAJ/JAMC 161 (II Suppl): S44-S50 (1999) (B2)

M Miralpeix et al.. Eur. Respir. J. 30. 359s (2007)D29a: Website of the European Respiratory Society, http://www.crs-cducation.org/cvcnts/intcma tional-congrcKs/stockholm-2007.aspx?idParc nt=2342 (B2)

MJ Telko et al., Respir. Care 50(9). 1209-27 (2005) (B2)

MR. Miller ct al., Eur. Respir. J. 26, 319-338 (2005) (B2)

O. Romain et al.. "Actualites pharmaceutiqucs?. Archives de pediatric. Elsevier. Paris.France, vol. 13. no. 12. December I, 2006. pages 1596-98. (B2)

P. Chancz ct al., Eur. Rcspir. J. 32, Suppl. 52 (2008) (B2)

P. Le Souef. Allergy 54 Suppl. 49:93-6 (1999) (B2)

P.W. Jones ct al.. Eur. Respir. J. 40. 830-836 (2012) (B2)

PJ. Atkins, Rcspir. Care 50(10), 1304-12 (2005) (B2)

Prescription information for the SPIRIVA Handihaler. 28 pages. September 2004 (B2)

Press release describing the findings disclosed in the Gavalda ct al.. Joos el al. Schelfhout et al. and Mirapeix ct al. communications described in D27 (B2)

Summary of Product Characteristics (SmPC) for "Duaklir Genuair 340 micrograms/12micrograms inhalation powder" (B2)

Summary of Product Characteristics (SmPC) for "Eklira Genuair 322 micrograms inhalation powder" (B2)

U.S. National Institutes of Health. "Efficacy and Safety of LAS 34273 in Patients with moderate to severe stable chronic obstructive pulmonary disease (COPD)", February 20, 2008 (B2)

U.S. National Institutes of Health: "A trial assessing LAS 34273 in moderate to severe stable chrome obstructive pulmonary disease (COPD)", February 20,2008 (B2)

V. Schelftout ct al.. Eur. Respir. J. 30. 356s (2007) (B2)

WO-A1-2005/014005 (B2)

WO-A1-2005/115466 (B2)

WO-A1-2008/096121 (B2)

WO-A1-2013/175013 (B2)

WO-A2-02/36106 (B2)

WO-A2-2008/102128 (B2)

WO-A2-2009/112273 (B2)

Website of the European Respirator)' Society, http://www.ers-cducation.org/evcnix/intcma tional-congrcxs/stockho!m-2007.aspx?idParc nt=2324 (B2)

Website of the European Respiratory Society, http://www.crs-cducation.org/cvcnts/intcma tional-congrcss/stockholm-2007.aspx?idParc nt=l425 (B2)

Website of the European Respiratory Society, http://www.ers-cducation.org/cvcnis/intcma tional-congrcKs/stockholm-2007.aspx (B2)

ANONYMOUS: 'European Pharmacopeia 7.0', part 2.9.18 deel ANONYMOUS: 'Preparations for inhalation: aerodynamic assessment of fine particles', pages 1 - 12 (B1)